Biogen beats estimates to make solid start to key year

25 April 2023
biogen_big

US biotech company Biogen (Nasdaq: BIIB) beat analysts’ expectations with its first-quarter 2023 financial results, exceeding forecasts with both sales and earnings figures.

The Boston-based firm recorded quarterly revenue of $2.46 billion, down 3% on a year ago but ahead of the Wall Street consensus estimate of $2.34 billion. Earnings per share dropped by 6% to $3.40, but again above the analyst estimate of $3.28.

"We continued to make strong progress against our business priorities, most importantly execution of three potential launches in 2023"Biogen reaffirmed its 2023 guidance, which is for a mid-single digit percentage decline in revenue versus 2022, and earnings per share of between $15 and $16.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology